Clinical Trial: Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
Study Status: Completed
Recruit Status: RECRUITING
Condition: Pathologically Confirmed Cancer Refractory to Conventional Therapy
Study Type: INTERVENTIONAL
Official Title: A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants With Pathologically Confirmed Cancer Refractory to Con
Brief Summary:
The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy.The main questions it aims to answer are:Is SNK02 safety and tolerable when administered weekly as an intravenous infusionWhat is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy…
Read more